Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2022 08:00 ET | Source: Certara

Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of...
June 28, 2022 08:00 ET | Source: Certara

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

PRINCETON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for...
June 21, 2022 08:00 ET | Source: Certara

Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

PRINCETON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Certara Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG),...
May 05, 2022 16:15 ET | Source: Certara

Certara Reports First Quarter 2022 Financial Results

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. ...
May 03, 2022 16:30 ET | Source: Certara

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor...
April 20, 2022 08:00 ET | Source: Certara

Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of...
March 01, 2022 16:15 ET | Source: Certara

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021...
February 23, 2022 16:30 ET | Source: Certara

U.S. FDA Licenses Certara’s Immunogenicity Simulator

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed...
February 22, 2022 01:26 ET | Source: Certara USA, Inc.

在过去8年中，美国FDA每一年批准的新药中90%来自Certara的客户

新泽西州普林斯顿 , Feb. 22, 2022 (GLOBE NEWSWIRE) -- 全球生物模拟领域的领军企业Certara, Inc.（纳斯达克股票代码：CERT），今日宣布在2021年美国食品药品监督管理局 (FDA) 药品审评和研究中心 (CDER)...
February 15, 2022 16:30 ET | Source: Certara

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...